Business Context and Reporting Period
Company: Bruker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Bruker designs and manufactures proprietary life science and materials research systems, including X-ray, magnetic resonance, mass spectrometry, and optical emission spectroscopy technologies. The company operates two primary segments: Scientific Instruments and Energy & Supercon Technologies. A significant event during the period was the acquisition of three former Varian product lines (chemical analysis business) from Agilent Technologies on May 19, 2010, for $37.5 million.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2010 |
Six Months Ended June 30, 2010 |
Six Months Ended June 30, 2009 |
|---|---|---|---|
| Total Revenue | $300.9 | $578.6 | $483.0 |
| Gross Profit | $135.7 | $262.0 | $213.9 |
| Gross Margin | 45.1% | 45.3% | 44.3% |
| Operating Income | $37.9 | $64.8 | $34.5 |
| Operating Margin | 12.6% | 11.2% | 7.1% |
| Net Income (Attributable to Bruker) | $22.6 | $38.7 | $21.3 |
| Diluted EPS | $0.14 | $0.23 | $0.13 |
| Cash from Operations | N/A | $53.1 | $51.3 |
| Total Debt (Long-term + Current) | $126.7 | $126.7 | $137.7 |
| Cash and Equivalents | $187.6 | $187.6 | $207.1 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 19.2% ($48.4M) for the quarter and 19.8% ($95.6M) for the six months compared to the prior year. Organic growth was driven by increased demand in magnetic resonance, X-ray, and mass spectrometry, as well as higher demand for low-temperature superconducting wire.
- Margin Expansion: Gross margins improved to 45.1% (Q2) and 45.3% (YTD) from 44.0% and 44.3% respectively, attributed to a favorable product mix shift toward high-end instrumentation and the weakening of the Euro against the USD.
- Operating Leverage: Operating expenses as a percentage of revenue decreased. SG&A dropped to 21.3% of revenue (Q2) from 23.9%, and R&D dropped to 10.4% from 12.3%, allowing operating margins to expand significantly.
- Acquisition Impact: The $37.5M acquisition of the chemical analysis business contributed approximately $3.7M to Q2 revenue and $10.5M to YTD revenue.
- Debt Reduction: Total debt decreased by approximately $11.0M in the first half of 2010, reducing interest expense.
Guidance, Outlook, and Risks
- Outlook: Management remains optimistic about the recovery in industrial markets and expects funding for academic and government research to remain stable or grow in key European markets despite spending reduction announcements.
- Capital Expenditures: Planned capital spending for 2010 is estimated between $20.0M and $30.0M. YTD spending of $10.7M is consistent with this plan.
- Liquidity: The company anticipates existing cash and credit facilities will be sufficient for the next 12 months. Available liquidity includes $242.8M under revolving loan arrangements.
- Risks and Contingencies:
- Foreign Exchange: Significant exposure to currency fluctuations, particularly the Euro and Swiss Franc, which impacted Q2 revenue negatively but improved gross margins.
- Tax Audits: Ongoing tax audits in Switzerland (2003-2006) and Germany (2003-2008) with uncertain timing and outcomes.
- Legal Proceedings: An age discrimination complaint filed by a former employee in Massachusetts; the MCAD found probable cause, and a conciliation conference is scheduled.
- Regulatory Compliance: The company temporarily lost Nasdaq compliance regarding Audit Committee independence due to a director resignation but regained compliance in August 2010.
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress and revenue contribution of the newly acquired chemical analysis business from Agilent.
- European Market Exposure: Monitor the impact of European government spending cuts on academic and government research budgets, a key customer base.
- Debt Covenants: Confirm continued compliance with the Credit Agreement's leverage (max 3.0) and interest coverage (min 3.0) ratios.
- Tax Position: Review the status of the $24.3M in unrecognized tax benefits and the outcome of ongoing audits in Germany and Switzerland.
- Inventory Levels: Assess the $424.5M inventory balance, particularly the $40.7M in demonstration units, for potential obsolescence risks.